

(sending institution please stamp here:)

patient label

name, date of birth, address

phone: ( \_\_\_\_\_ ) \_\_\_\_\_ - \_\_\_\_\_ extension please

GHSG Studienzentrale  
Uniklinik Köln

50924 Köln  
Germany

phone: +49 221 / 478-88166  
fax: +49 221 / 478-88188

## EXCLUSION CRITERIA

date of histological findings

day	month	year

# EX

**Trial: AVD-Rev**

**Case ID: CRF ID:**

### Exclusion criteria:

	yes	no
1. Nodular Lymphocyte predominant Hodgkin Lymphoma	<input type="checkbox"/>	<input type="checkbox"/>
2. Hodgkin Lymphoma as part of a composite lymphoma	<input type="checkbox"/>	<input type="checkbox"/>
3. Any prior use of lenalidomide or prior chemo- or radiation therapy	<input type="checkbox"/>	<input type="checkbox"/>
4. Concurrent use of other anti-cancer agents or treatments	<input type="checkbox"/>	<input type="checkbox"/>
5. Simultaneous participation on other trials within the last 30 days except follow-up	<input type="checkbox"/>	<input type="checkbox"/>
6. Use of any other experimental drug or therapy within 28 days of baseline	<input type="checkbox"/>	<input type="checkbox"/>
7. Known positive for HIV or chronic infectious hepatitis, type B or C (unless seropositivity due to vaccination)	<input type="checkbox"/>	<input type="checkbox"/>
8. Severe cardiac disease, e.g. cardiomyopathy, cardiac insufficiency (EF <50% or FS < 25% in 2D-Echocardiography, NYHA class 3 or 4 failure)	<input type="checkbox"/>	<input type="checkbox"/>
9. Severe uncontrolled arterial hypertension (WHO 3rd degree)	<input type="checkbox"/>	<input type="checkbox"/>
10. Uncontrolled infections	<input type="checkbox"/>	<input type="checkbox"/>
11. Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form	<input type="checkbox"/>	<input type="checkbox"/>
12. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she/he were to participate in the study or confounds the ability to interpret data from the study	<input type="checkbox"/>	<input type="checkbox"/>
13. Known hypersensitivity to thalidomide	<input type="checkbox"/>	<input type="checkbox"/>
14. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs	<input type="checkbox"/>	<input type="checkbox"/>
15. Pregnant or breast feeding females	<input type="checkbox"/>	<input type="checkbox"/>
16. Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate)	<input type="checkbox"/>	<input type="checkbox"/>
17. Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate her/his own wishes correspondingly	<input type="checkbox"/>	<input type="checkbox"/>
18. Non-compliance: refusal of blood products during treatment, epilepsy, drug dependency, change of residence to abroad, prior cerebral injury or similar circumstances that appear to make protocol treatment or long-term follow-up impossible	<input type="checkbox"/>	<input type="checkbox"/>
19. Antiepileptic treatment	<input type="checkbox"/>	<input type="checkbox"/>
20. Patients who have a relationship of dependence or employer-employee relationship to the sponsor or the investigator	<input type="checkbox"/>	<input type="checkbox"/>
21. Commitment to an institution on judicial or official order	<input type="checkbox"/>	<input type="checkbox"/>

day	month	year

Investigator signature